Nicotinamide riboside/Pterostilbene

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameNicotinamide riboside/Pterostilbene
Drug Alias NameBasisEH-301
ClassificationSmall molecules
Mechanisms of ActionNAD-dependent protein deacetylase sirtuin-5 inhibitorsNAD(Nicotinamide adenine dinucleotide) modulators
TargetsNAD(Nicotinamide adenine dinucleotide)NAD-dependent protein deacetylase sirtuin-5
Therapy Area/IndicationsAcute Kidney Injury
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Nicotinamide riboside
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesElysium Health
China Registration ClassN/A

Develop Information

Active CompaniesElysium Health
Inactive CompaniesN/A
Active IndicationsAcute Kidney Injury
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A